Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525306 | 0.94 | F2 (0.35) | F2SLC6A9DDR1BDKRB1TBXA2R | |
| SCHEMBL3408137 | 0.91 | DDR1 (0.36) | F2DDR1BDKRB1 | |
| SCHEMBL3407614 | 0.89 | CACNA2D1 (0.34) | F2SLC6A9CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3405699 | 0.84 | BACE1 (0.41) | F2SLC6A9 | |
| SCHEMBL6521493 | 0.84 | F2 (0.37) | F2SLC6A9DDR1 | |
| SCHEMBL3401743 | 0.84 | BACE1 (0.37) | F2 | |
| SCHEMBL3403098 | 0.83 | BACE1 (0.36) | F2SLC6A9DDR1TBXA2RCACNA2D1 | |
| SCHEMBL3409864 | 0.83 | F2 (0.38) | F2SLC6A9DDR1 | |
| SCHEMBL3403100 | 0.82 | BACE1 (0.38) | F2DDR1 | |
| SCHEMBL3406126 | 0.82 | F2 (0.38) | F2DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | F2 1098/4885SLC6A9 379/4885DDR1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.